Goldman Sachs downgraded Arm to Sell and cut its price target to $120, citing limited leverage to the AI spending cycle. The firm said Arm licensing-heavy model is less exposed to AI hardware upside than chipmakers directly tied to AI production, tempering its growth outlook.